drugset
drugset / Trial / NCT06189209

Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

NCT06189209 ↗

Phase 2 Recruiting 40 enrolled Rhizen Pharmaceuticals SA Incozen Therapeutics Pvt Ltd · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting.

Timeline

Start
2024-03-04
Primary completion
2026-12-31
Completion
2027-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenalisib Small molecule 400 mg Oral
Subject Tenalisib Small molecule 800 mg Oral

Indications

triple-negative breast carcinoma